Business Description
RaQualia Pharma Inc
ISIN : JP3967150008
Total Employee Number:
103Description
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.61 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.35 | |||||
Debt-to-EBITDA | -12.81 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.93 | |||||
Beneish M-Score | -2.06 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6 | |||||
3-Year EBITDA Growth Rate | -5.1 | |||||
3-Year EPS without NRI Growth Rate | -33.6 | |||||
3-Year Book Growth Rate | 2.5 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.72 | |||||
9-Day RSI | 47.36 | |||||
14-Day RSI | 40.95 | |||||
3-1 Month Momentum % | -39.36 | |||||
6-1 Month Momentum % | -52.1 | |||||
12-1 Month Momentum % | -7.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.16 | |||||
Quick Ratio | 6.01 | |||||
Cash Ratio | 4.27 | |||||
Days Inventory | 174.19 | |||||
Days Sales Outstanding | 334.65 | |||||
Days Payable | 65.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.3 | |||||
Shareholder Yield % | -7.25 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.67 | |||||
Operating Margin % | -32.31 | |||||
Net Margin % | -41.91 | |||||
EBITDA Margin % | -15.86 | |||||
FCF Margin % | 19.23 | |||||
OCF Margin % | 22.97 | |||||
ROE % | -8.6 | |||||
ROA % | -5.56 | |||||
ROIC % | -6.83 | |||||
3-Year ROIIC % | -8.85 | |||||
ROC (Joel Greenblatt) % | -25 | |||||
ROCE % | -4.88 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 9.94 | |||||
Price-to-Owner-Earnings | 58.5 | |||||
PS Ratio | 8.54 | |||||
PB Ratio | 1.55 | |||||
Price-to-Tangible-Book | 2.83 | |||||
Price-to-Free-Cash-Flow | 46.21 | |||||
Price-to-Operating-Cash-Flow | 38.17 | |||||
EV-to-EBIT | -24.1 | |||||
EV-to-EBITDA | -49.65 | |||||
EV-to-Revenue | 7.88 | |||||
EV-to-FCF | 40.95 | |||||
Price-to-GF-Value | 0.5 | |||||
Price-to-Projected-FCF | 1.91 | |||||
Price-to-Median-PS-Value | 0.76 | |||||
| Price-to-Net-Current-Asset-Value | 3.94 | |||||
| Price-to-Net-Cash | 10.52 | |||||
Earnings Yield (Greenblatt) % | -4.15 | |||||
FCF Yield % | 2.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
RaQualia Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 1,372.556 | ||
| EPS (TTM) (円) | -24.09 | ||
| Beta | -0.1796 | ||
| 3-Year Sharpe Ratio | 0.01 | ||
| 3-Year Sortino Ratio | 0.01 | ||
| Volatility % | 87.4 | ||
| 14-Day RSI | 40.95 | ||
| 14-Day ATR (円) | 20.114929 | ||
| 20-Day SMA (円) | 478.1 | ||
| 12-1 Month Momentum % | -7.02 | ||
| 52-Week Range (円) | 440 - 1465 | ||
| Shares Outstanding (Mil) | 26.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
RaQualia Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
RaQualia Pharma Inc Stock Events
| Event | Date | Price (円) | ||
|---|---|---|---|---|
| No Event Data | ||||
RaQualia Pharma Inc Frequently Asked Questions
What is RaQualia Pharma Inc(TSE:4579)'s stock price today?
The current price of TSE:4579 is 円481.00. The 52 week high of TSE:4579 is 円1465.00 and 52 week low is 円440.00.
When is next earnings date of RaQualia Pharma Inc(TSE:4579)?
The next earnings date of RaQualia Pharma Inc(TSE:4579) is .
Does RaQualia Pharma Inc(TSE:4579) pay dividends? If so, how much?
RaQualia Pharma Inc(TSE:4579) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on RaQualia Pharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers